Effect of combination treatment with a vitamin D analog (OCT) and a bisphosphonate (AHPrBP) in a nude mouse model of cancer-associated hypercalcemia

Journal of Bone and Mineral Research

Volumn 13, Issue 9, 1998, Pages 1378-1383

  Endo, Koichi ^a   Katsumata, Kyoko ^a   Iguchi, Haruo ^b   Kubodera, Noboru ^a   Teramoto, Tamio ^c   Ikeda, Kyoji ^d,e   Fujita, Toshiro ^d   Ogata, Etsuro ^f  

^a CHUGAI PHARMACEUTICAL CO LTD   (Japan)

^b NATIONAL KYUSHU CANCER CENTER   (Japan)

^c TEIKYO UNIVERSITY   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

^e NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY   (Japan)

^f CANCER INSTITUTE HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

22 OXACALCITRIOL; BISPHOSPHONIC ACID DERIVATIVE; PAMIDRONIC ACID; VITAMIN D DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CACHEXIA; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; HYPERCALCEMIA; LUNG SQUAMOUS CELL CARCINOMA; MALE; MALIGNANT NEOPLASTIC DISEASE; MOUSE; NONHUMAN; NUDE MOUSE; OSTEOLYSIS; PANCREAS CARCINOMA; PHARYNX CARCINOMA;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CACHEXIA; CALCITRIOL; CALCIUM; CARCINOMA, SQUAMOUS CELL; DIPHOSPHONATES; DRUG SYNERGISM; HUMANS; HYPERCALCEMIA; LUNG NEOPLASMS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PANCREATIC NEOPLASMS; PARATHYROID HORMONE-RELATED PROTEIN; PHARYNGEAL NEOPLASMS; PROTEINS;

EID: 0031662240     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.1998.13.9.1378     Document Type: Article

References (19)

1. Broadus AE, Mangin M, Ikeda K, Insogna KL, Weir EC, Burtis WJ, Stewart AF 1988 Humoral hypercalcemia of cancer: Identification of a novel parathyroid hormone-like peptide. N Engl J Med 319:556-563.
2. Tisdale MJ 1991 Cancer cachexia. Br J Cancer 63:337-343.
3. Spiegelman BM, Hotamisligil GS 1993 Through thick and thin: Wasting, obesity, and TNFα. Cell 73:625-627.
4. Strassmann G, Fong M, Kenney JS, Jacob CO 1992 Evidence for the involvement of interleukin 6 in experimental cancer cachexia. J Clin Invest 89:1681-1684.
5. Mori M, Yamaguchi K, Hoda S, Nagasaki K, Ueda M, Abe O, Abe K 1991 Cancer cachexia syndrome developed in nude mice bearing melanoma cells producing leukemia-inhibitory factor. Cancer Res 51:6656-6659.
6. Fleisch H 1987 Bisphosphonates: History and experimental basis. Bone 8(Suppl):523-528.
7. Endo K, Ichikawa F, Uchiyama Y, Katsumata K, Ohkawa H, Kumaki K, Ogata E, Ikeda K 1994 Evidence for the uptake of a vitamin D analogue (OCT) by a human carcinoma and its effect of suppressing the transcription of parathyroid hormone-related peptide gene in vivo. J Biol Chem 269:32693-32699.
8. Haq M, Kremer R, Goltzman D, Rabbani SA 1993 A vitamin D analogue (EB1089) inhibits parathyroid hormone-related peptide production and prevents the development of malignancy-associated hypercalcemia in vivo. J Clin Invest 91:2416-2422.
9. 3 analogues. Chem Pharmacol Bull 34: 4410-4413.
10. Nagata N, Akatsu T, Kugai N, Yasumoto Y, Kinoshita T, Kosano H, Shimauchi T, Takatani O, Ueyama Y 1989 The tumor cells (FA-6) established from a pancreatic cancer associated with humoral hypercalcemia of malignancy: A simultaneous production of parathyroid hormone-like activity and transforming growth factor activity. Endocrinol Jpn 36:75-85.
11. Ichinose Y, Iguchi H, Ohta M, Katakami H 1993 Establishment of lung cancer cell line producing parathyroid hormone-related protein. Cancer Lett 74:119-124.
12. Tashiro T, Inaba M, Kobayashi T, Sakurai Y, Maruo K, Ohnishi Y, Ueyama Y, Nomura T 1989 Responsiveness of human cancer/nude mouse to antitumor agents in a model using clinically equivalent doses. Cancer Chemother Pharmacol 24:187-192.
13. Ikeda K, Ohno H, Hane M, Yokoi H, Okada M, Honma T, Yamada A, Tatsumi Y, Tanaka T, Saitoh T, Hirose S, Mori S, Takeuchi Y, Fukumoto S, Tarukina S, Iguchi H, Kiriyama T, Ogata E, Matsumoto T 1994 Development of a sensitive two-site immunoradiometric assay for parathyroid hormone-related peptide: Evidence for elevated levels in plasma from patients with adult T-cell leukemia/lymphoma and B-cell lymphoma. J Clin Endocrinol Metab 79:1322-1327.
14. Inoue D, Matsumoto T, Ogata E, Ikeda K 1993 22-Oxacalcitriol, a noncalcemic analogue of calcitriol, suppresses both cell proliferation and parathyroid hormone-related peptide gene expression in human T cell lymphotrophic virus, type I-infected t cells. J Biol Chem 268:16730-16736.
15. Fleisch H 1995 Osteolytic tumor bone disease. In: Fleisch H (ed.) Bisphosphonates in Bone Disease: From the Laboratory to the Patient. The Parthenon Publishing Group, New York, NY, U.S.A., pp. 86-109.
16. Dusso AS, Negrea L, Gunawardhana S, Lopez-Hilker S, Finch J, Mori T, Nishii Y, Slatopolsky E, Brown AJ 1991 On the mechanisms for the selective action of vitamin D analogs. Endocrinology 128:1687-1692.
17. 3, in rats. J Biochem 115:373-380.
18. Bikle DD 1992 Vitamin D: New actions, new analogs, new therapeutic potential. Endocr Rev 13:765-784.
19. Nussbaum SR, Younger J, VandePol CJ, Gagel RF, Zubler MA, Chapman R, Henderson IC, Mallette LE 1993 Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: Comparison of 30-, 60-, and 90-mg dosages. Am J Med 95:297-304.